Last Updated : December 18, 2024
Date: Tuesday, December 17
Time: 2:00 p.m. to 3:15 p.m. ET
The Drug Reimbursement Review process at Canada’s Drug Agency plays a critical role in the pathway that helps patients access new drugs. In June 2023, we signalled program improvements that could be explored or added to the process. Since that time, we have been engaging interested parties to identify further improvements and new approaches to reduce review timelines, while maintaining the rigorous scientific methods for which we are known.
On December 17, 2024, join Peter Dyrda (Director, Pharmaceutical Reviews) and Michelle Gibbens (Director, Engagement) for information on improvements to our program that aim to accelerate patient access to new medications and streamline our processes.
This webinar is a preconsultation event for patient organizations. The program changes presented during the virtual event will be fully described in a consultation document that will be posted on our website on January 6, 2025, for feedback from all interested parties.
This free virtual event will take place on December 17, 2024, between 2:00 p.m. and 3:15 p.m. ET and is open to all interested parties, but we will prioritize questions and comments from individuals representing patient organizations.
Last Updated : December 18, 2024